Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Update on didanosine.

David A Cooper1

  • 1National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia. d.cooper@nchecr.unsw.edu.au

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)
|August 29, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cryopreservation of siRNA-Treated Cells Is Feasible.

Nucleic acid therapeutics·2025
Same author

Optimized chemical structure extends silencing duration of therapeutic siRNAs in dividing cancer and immune cells.

Molecular therapy : the journal of the American Society of Gene Therapy·2025
Same author

Intracellular Pocket Conformations Determine Signaling Efficacy through the μ Opioid Receptor.

Journal of chemical information and modeling·2025
Same author

Ligand Reorganization for End-Point Binding Free Energy Calculations: Identifying Preferred Poses of Fentanyls in the μ Opioid Receptor.

Journal of chemical theory and computation·2025
Same author

Intracellular pocket conformations determine signaling efficacy through the <math></math> opioid receptor.

bioRxiv : the preprint server for biology·2024
Same author

Dendritic amphiphilic siRNA: Selective albumin binding, <i>in vivo</i> efficacy, and low toxicity.

Molecular therapy. Nucleic acids·2023
Same journal

Cryptococcal antigen screening and preemptive therapy in patients initiating antiretroviral therapy in resource-limited settings: a proposed algorithm for clinical implementation.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
Same journal

Factors associated with false-positive results from fingerstick OraQuick ADVANCE rapid HIV 1/2 antibody test.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
Same journal

Greater acceptance of routine HIV testing (opt-out) by patients attending an infectious disease unit in Spain.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
Same journal

Once-daily nevirapine XR: a brief overview of the safety and efficacy of a new formulation.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
Same journal

Thalidomide-associated thrombosis in the treatment of HIV-associated severe aphthous disease: a case report and review of the literature.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
Same journal

Choosing sides: HIV health care practices among shared populations of HIV-positive Latinos living near the US-Mexico border.

Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)·2012
See all related articles

Didanosine (ddl) remains a key component in HIV treatment, offering long-term efficacy in combination therapy. Newer formulations allow once-daily dosing, improving patient compliance and outcomes in managing HIV infection.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Virology

Background:

  • Didanosine (ddl) has been a vital antiretroviral agent since 1991.
  • Initially an alternative to zidovudine (ZDV), ddl is now integral to combination HIV therapy.
  • Recent advancements include once-daily dosing formulations like Videx EC.

Purpose of the Study:

  • To review recent studies on didanosine in combination anti-HIV therapy.
  • To examine the rationale for ddl as first-line HIV treatment.
  • To update findings on ddl's long-term efficacy, safety, compliance, resistance, and dosing.

Main Methods:

  • Review of recently published studies on didanosine use.
  • Analysis of data concerning efficacy, side effects, compliance, resistance, and dosing.

Related Experiment Videos

  • Focus on combination anti-HIV therapy regimens.

    • Main Results:

    • Didanosine (ddl) is extensively used in multidrug regimens for adults and children with HIV.
    • Newer formulations enable once-daily administration, enhancing convenience.
    • Long-term clinical efficacy of ddl contributes to increased survival in HIV-infected patients.

    Conclusions:

    • Didanosine (ddl) continues to be a cornerstone in HIV management due to its long-term efficacy.
    • Once-daily dosing of ddl improves treatment adherence and outcomes.
    • Combination therapy including ddl is crucial for improved survival in HIV patients.